View Older Stories View More Recent Stories
-
Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment
-
Florida sues Pfizer over Covid-19 vaccine safety claims
-
Florida attorney general sues Pfizer over COVID-19 vaccine marketing claims
-
Trump praises Lilly, Merck, Pfizer investments
-
Pfizer to present 45 cancer abstracts at ESMO 2026 congress
-
PFE builds bull case at $26 after earnings beat and insider buys
-
Trump Administration Weighs Order On Autism And Vaccines - Bloomberg
-
Pfizer (PFE) Tops Q2 EPS by 9c, Beats on Revenue; Offers FY26 EPS Guidance
-
Pfizer Q2 earnings preview: Analysts eye pipeline updates, portfolio resilience
-
Pfizer (PFE) call put ratio 1.1 calls to 1 put into quarter results
-
Pfizer (PFE) call put ratio 1.9 calls to 1 put into quarter results
-
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
-
Pfizer temporarily discontinues premarin vaginal cream in India, citing supply challenges - Reuters
-
Pfizer (PFE) PT Lowered to $30 at BMO Capital
-
Pfizer (PFE) PT Lowered to $35 at Guggenheim
-
HSBC Downgrades Pfizer (PFE) to Hold
-
FDA: approves Pfizer's palbociclib (ibrance) with trastuzumab for HR-positive, her2-positive metastatic breast cancer
-
Enanta Pharma loses appeal in Pfizer Paxlovid patent case
-
Pfizer executive says China now leads Europe in drug innovation
-
BMO Capital on Pfizer (PFE): 'SigVie Trial Misses on OS With Signs of Benefit for Future Trials'
-
Pfizer (PFE) Reiterated at Neutral by Cantor Fitzgerald on Negative SV Data
-
Pfizer reafffirms 2026 guidance after CFO transition announcement
-
Pfizer reaffirms 2026 guidance after CFO transition news
-
Arvinas and Pfizer complete Rigel license deal for vepdegestrant
-
German government to drop variable drug discounting plans - Reuters
-
RBC Capital Upgrades Pfizer (PFE) to Sector Perform
-
ADA 2026 preview: All eyes on these 2 stocks
-
Pfizer (PFE) Reiterates at Neutral by Cantor Fitzgerald
-
Pfizer drug combination cuts prostate cancer progression risk by 52%
-
Pfizer's BRAFTOVI regimen shows improved survival in colorectal cancer
-
Morgan Stanley: China healthcare sector dips 1.3% amid licensing scrutiny
-
Pfizer's LORBRENA shows 55% seven-year survival without progression
-
UBS Reiterates Neutral Rating on Pfizer (PFE)
-
Arvinas Inc. (ARVN) PT Raised to $16 at BofA Securities
-
European Commission approves Pfizer's HYMPAVZI for hemophilia with inhibitors
-
FDA Commissioner Marty Makary to step down - Politico
-
Arvinas and Pfizer sell VEPPANU rights to Rigel for $85 million upfront
-
MBX Biosciences (MBX) PT Raised to $86 at Citizens on 'Good' MBX 4291 Update
-
HHS downplays Hantavirus risk amid repatriation efforts
-
Health officials explore restrictions on certain SSRI antidepressants - Reuters
-
Novo Nordisk Eyes Large-Scale M&A Following Pfizer's Metsera Win - Semafor
-
Pfizer (PFE) PT Raised to $27 at BofA Securities
-
Pfizer Reviewing New Molecule It Designed Using AI - CEO
-
Pfizer beats first quarter estimates on strong product growth
-
Pfizer (PFE) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
-
Pfizer (PFE) call put ratio 4.7 calls to 1 put quarter results
-
Pfizer (PFE) calls more active than puts into quarter results
-
Pfizer (PFE) call put ratio 2.9 calls to 1 put with a focus on May 8 weekly 27 calls into quarter results
-
Pfizer's ELREXFIO meets primary endpoint in multiple myeloma trial
-
Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'
